Evidence map›Paper›PMID 40620498›Full record

ArticleLiver research (Beijing, China)2025

Rhizoma Atractylodis Macrocephalae reduces HFD-induced MAFLD in mice through activated AMPK-mediated inhibition of fatty acid synthesis.

Ke Zheng, Ruishuo Zhang, Yijing Xin, Yuge Zhou, Jiacheng Lin, Weifan Huang, Fang Wang, Liu Yang, Xuehua Sun, Xiaoni Kong

Abstract read
In one paragraph

Article in Liver research (Beijing, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cotinine Promotes Cancer Cell Proliferation and mEnvironment & health (Washington, D.C.) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ke ZhengCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ruishuo ZhangThe First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China.
Yijing XinCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yuge ZhouCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jiacheng LinCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Weifan HuangCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Fang WangCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Liu YangCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xuehua SunCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaoni KongCentral Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common chronic condition that can lead to cancer due to its complex pathogenesis. Therapeutic agents targeting AMP-activated protein kinase (AMPK) activation have been suggested as potential treatments for metabolic disorders such as metabolic dysfunction-associated steatohepatitis (MASH). Rhizoma Atractylodis Macrocephalae (RAM) has been clinically used to treat obesity-related health problems, but its therapeutic effects on MAFLD and the underlying mechanism remain unclear. Therefore, this study was conducted to evaluate the function and underlying mechanism of RAM in the treatment of MAFLD. Methods: The effect of RAM decoction on MAFLD was evaluated using a high-fat diet (HFD)-induced MAFLD mouse model. Results: Administration of RAM decoction significantly reduced body weight gain in MAFLD mice without changing food intake. The weights of the liver and inguinal adipose tissues were also reduced after RAM treatment. Additionally, RAM administration decreased serum levels of alanine aminotransferase, aspartate transaminase, total cholesterol, triglyceride, low-density lipoprotein cholesterol, and glucose, while reducing lipid droplet accumulation in the liver tissues of MAFLD mice. The underlying mechanisms included the activation of the phosphorylation of AMPK and acetyl-CoA carboxylase (ACC), and inhibition of the expression of sterol regulatory element binding protein 1 (SREBP1). However, RAM did not alter the protein expression levels of peroxisome proliferator-activated receptor α and carnitine palmitoyltransferase-1α. Furthermore, the RAM-induced upregulation of phosphorylated AMPK, phosphorylated ACC, and SREBP1 expression, as well as the downregulation of fatty acid synthase expression, were reversed by using an AMPK inhibitor. Conclusions: Through a combination of network pharmacology and experimental validation, we demonstrated that RAM may exert therapeutic effects on MAFLD by inhibiting lipid synthesis and activating phosphorylated AMPK pathways.

Indexed as

AMP-activated protein kinase (AMPK)Hepatic steatosisMetabolic dysfunction-associated fatty liver disease (MAFLD)Rhizoma Atractylodis Macrocephalae (RAM)

Identifiers

PMID40620498
PMCPMC12226795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.